Abstract Genetic deficiency of the SLC26A1 anion exchanger in mice is known to be associated with hyposulfatemia and hyperoxaluria with nephrolithiasis, but many aspects of human SLC26A1 function remain to be explored. We report here the functional characterization of hum a n S L C 2 6 A 1 , a 4 , 4 ′ -d i i s o t h i o c y a n a t o -2 , 2 ′ -stilbenedisulfonic acid (DIDS)-sensitive, electroneutral sodium-independent anion exchanger transporting sulfate, oxalate, bicarbonate, thiosulfate, and (with divergent properties) chloride. Human SLC26A1-mediated anion exchange differs from that of its rodent orthologs in its stimulation by alkaline pH o and inhibition by acidic pH o but not pH i and in its failure to transport glyoxylate. SLC26A1-mediated transport of sulfate and oxalate is highly dependent on allosteric activation by extracellular chloride or non-substrate anions. Extracellular chloride stimulates apparent V max of human SLC26A1-mediated sulfate uptake by conferring a 2-log decrease in sensitivity to inhibition by extracellular protons, without changing transporter affinity for extracellular sulfate. In contrast to SLC26A1-mediated sulfate transport, SLC26A1-associated chloride transport is activated by acid pH o , shows reduced sensitivity to DIDS, and exhibits cation dependence of its DIDS-insensitive component. Human SLC26A1 resembles SLC26 paralogs in its inhibition by phorbol ester activation of protein kinase C (PKC), which differs in its undiminished polypeptide abundance at or near the oocyte surface. Mutation of SLC26A1 residues corresponding to candidate anion binding site-associated residues in avian SLC26A5/prestin altered anion transport in patterns resembling those of prestin. However, rare SLC26A1 polymorphic variants from a patient with renal Fanconi Syndrome and from a patient with nephrolithiasis/calcinosis exhibited no loss-of-function phenotypes consistent with disease pathogenesis.
Introduction
The highly conserved human SLC26 gene family includes 11 members encoding at least 10 polypeptide gene products that mediate electroneutral or electrogenic anion transport in many cell and tissue types [15] . The SLC26 proteins are Nglycosylated [43] homodimers [14] (or tetramers [5, 78] ) with short N-terminal cytoplasmic domains followed by 14 transmembrane spans and C-terminal cytoplasmic STAS domains of variable length [3, 23] . Mammalian SLC26 proteins transport small anion substrates including Cl 
oxalate, I
− , and formate [55] , whereas SLC26-related SulP proteins transport dicarboxylates as well [35, 74] , playing important roles in maintaining cellular anion homeostasis [15] . Human SLC26 mutations cause Mendelian diseases such as diastrophic (chondro)dysplasia (SLC26A2) [4] , congenital chloride diarrhea (SLC26A3) [80] , Pendred syndrome or isolated enlargement of the vestibular acqueduct (SLC26A4) [8, 79] , and impaired male fertility (SLC26A8) [21] . SLC26A9 is a risk modifier gene for cystic fibrosis [9, 77] , and SLC26A11 polypeptide has been implicated in the neuronal swelling of cerebral edema [66] . In mice, genetically engineered loss of function led to outer hair cell deafness (Slc26a5) [44] , oxalate urolithiasis (Slc26a6, Slc26a1) [18, 33] , and distal renal tubular acidosis (Slc26a7, Slc26a9) [83, 84] . SLC26A1/SAT1 cDNA was first cloned from rat liver as a Na + -independent SO 4 2− transporter [7] . Human SLC26A1 exhibits modest cross-species conservation of amino acid sequence, sharing 78 % identity with rat SLC26A1 and 77 % with mouse SLC26A1, but only 44 % identity with paralogous human SO 4 2− transporter SLC26A2 [60] . Previous studies of human and rodent SLC26A1 have demonstrated electroneutral, pH-regulated exchange of anions including SO 4 2− , oxalate, HCO 3 − , thiosulfate, and glyoxylate, sensitive to inhibition by 4,4′-diisothiocyanato-2,2′-stilbenedisulfonic acid (DIDS) [39-41, 60, 70, 82] . However, the ability of SLC26A1 to transport Cl − remains controversial, with reports both detecting [41, 60] and failing to detect Cl − transport [40, 50, 82] . An unusual property of rodent SLC26A1-mediated SO 4 2− uptake measured in Xenopus oocytes is cis-stimulation by extracellular Cl − [69] , as well as by other non-substrate anions, including Br
− , formate, and lactate [82] . The mechanism of this cisstimulation has remained unclear.
SO 4 2− is an essential nutrient for development [16] , biosynthetic sulfation [27] , and hepatic sulfate conjugation reactions [24] . The widely expressed SLC26A1 is particularly abundant in sinusoidal membranes of hepatocytes and in basolateral membranes of intestinal enterocytes and renal proximal tubular cells, with higher expression in male than female rats [12, 36, 41, [59] [60] [61] . The liver is also the main site of oxalate uptake from dietary absorption, oxalate biosynthesis from ascorbate and amino acid metabolism, and oxalate catabolism [52, 76] . Hepatic SLC26A1 is the likely sinusoidal exchanger of intracellular oxalate for extracellular SO 4 2− , enabling SO 4 2− uptake and oxalate secretion for eventual excretion by intestine and kidney [11] . Renal glomeruli freely filter both SO 4 2− and oxalate. Most filtered SO 4 2− is reabsorbed by renal proximal tubular cells, which also secrete oxalate [6, 31, 37, 71] . SLC26A1 in proximal tubular cell basolateral membrane likely mediates basolateral SO 4 2− efflux into the pericapillary interstitial space, in exchange for uptake of extracellular oxalate, which can then be secreted across the apical membrane by SLC26A6 [47] . Slc26a1 −/− mice exhibited urolithiasis, hyperoxaluria, hyperoxalemia, hyposulfatemia, hypersulfaturia, and increased susceptibility to hepatotoxicity [18] . However, oxalate secretion by isolated Slc26a1 −/− duodenum was unchanged [38] , and Slc26a1 mRNA and protein abundance was unaltered in mice with hyperoxaluria of other causes, questioning the physiological role of SLC26A1 in hyperoxaluria (at least in duodenum) [22] . Human diseases caused by SLC26A1 mutations have not been reported.
In the present study, we further delineate the function and regulation of human SLC26A1 expressed in Xenopus oocytes, and test potential pathogenicity of selected candidate disease-associated missense variants. We report that extracellular Cl − allosterically activates SLC26A1 by increasing SLC26A1 V max for SO 4 2− transport without change in K 1/2 for SO 4 2−
[o] . The increased V max reflects a 2 log decrease in sensitivity of SO 4 2− /anion exchange to inhibition by extracellular protons.
Methods

Materials
Na
36
Cl and H 36 Cl were from ICN (Irvine, CA) and Na 2 35 SO 4 from ARC (Saint Louis, MO). 14 C-oxalate originally from NEN-DuPont (Boston, MA) was a gift from Scheid and Honeyman (Univ. Mass. Med. Ctr.). Restriction enzymes and T4 DNA ligase were from New England Biolabs (Beverly, MA). EXPAND High-fidelity PCR System was from Roche Diagnostics (Indianapolis, IN). QuikChange II XL site-directed mutagenesis kit was from Agilent Technologies (Lexington, MA). MEGAscript® T7 Transcription Kit was from Thermo Fisher Scientific (Waltham, MA). 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) was from Calbiochem (La Jolla, CA). Phorbol-12-myristate-13-acetate (PMA) was from LC Laboratories (Woburn, MA). Niflumic acid (NFA), glyoxylate, dibutyryl cyclic AMP sodium salt (dB-cAMP), 3-isobutyl-1-methylanxthine (IBMX), tenidap, and 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM) were from Santa Cruz Biotechnology (Dallas, TX). Hydrochlorothiazide (HCTZ) and R-(+)-[(2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]-acetic acid (DIOA) were from Sigma (St. Louis, MO). DMSO Stock solutions of these drugs were stored at −20°C. All other chemical reagents were from Sigma or Fluka (Milwaukee, WI) and were of reagent grade.
Solutions
Modified Barth's saline (MBS) consisted of (mM) 85 . Addition of sodium butyrate (40 mM) was in mole-for-mole substitution for NaCl. ND96 solutions at pH 5.0 and 6.0 were buffered with 5 mM MES. ND96 solutions at pH values of 8.0 through 9.5 were buffered with 5 mM tricine.
Construction and mutagenesis of cDNA expression plasmids
Human SLC26A1 (NM_022042) was subcloned into the Xenopus oocyte expression vector pXT7. pXT7-SLC26A1 with a fused N-terminal HA-tag was constructed by PCR mutagenesis and ligation. SLC26A1 mutations C41W, A56T, M132T, E295Q, A400C, K401E, and Q556R were generated by QuikChange II XL site-directed mutagenesis kit using specific mutagenic oligonucleotides. (See Table S1 for oligonucleotide primer sequences).
Expression of cRNA in Xenopus oocytes
SLC26A1 cRNA and Xenopus oocytes were prepared as previously described [30] . Oocytes injected with 50 nl cRNA (1-40 ng) and uninjected oocytes were maintained at 17.5°C in MBS containing gentamicin for 2-5 days before use. Control uninjected and control water-injected oocytes exhibited indistinguishable levels of influx of 
Isotopic influx experiments
Oocytes were prewashed (<1 min) in radioisotope-free influx medium to avoid introduction of trace (Cl − -containing) MBS to the influx assay. 35 Chemicals and drugs were diluted to the indicated concentrations in influx bath solution before uptake experiments. Influx experiments were terminated with 3 washes in cold ND96(cyclamate), followed by oocyte lysis in 150 μl of 2 % sodium dodecyl sulfate (SDS). Triplicate 10 μl aliquots of influx solution (in 150 μl 2 % SDS) were used to calculate specific activities of radiolabeled substrate anions. Oocyte anion uptake was calculated from oocyte-associated counts per minute (cpm) and bath specific activity. Cl (5000-8000 cpm). After 5 min recovery in ND96(gluconate), oocytes were transferred into fresh efflux solutions and the assay was carried out as above. For 14 Coxalate efflux assays, oocytes were injected with 50 nl of 100 mM Na 14 C-oxalate (8000-10,000 cpm, with final estimated intracellular concentration 10 mM). After a recovery period of at least 15 min, efflux was measured as above.
Isotopic efflux experiments
To vary oocyte pH i , oocytes were pre-exposed to 40 mM Na butyrate (substituting for NaCl) for 30 min before initiation of an efflux experiment to produce intracellular acidification of 0.5 pH units to pH i~6 .7-6.8 [75] . Upon removal of bath butyrate (with substitution by NaCl) during the efflux experiment, pH i alkalinized back towards initial pH i while pH o remained constant.
Efflux data were plotted and anion efflux rate constants were calculated as previously reported [30] .
Confocal immunofluorescence microscopy
Three or four days after injection with cRNA encoding wildtype or mutant HA-SLC26A1, 10-12 oocytes were fixed with 1.5 % paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 30 min at room temperature and washed three times with PBS containing 0.002 % Na azide (PBS azide). Oocytes were then placed in PBS containing 1 % SDS for 15 min to further permeabilize the surface membrane and unmask epitopes. After three subsequent washes in PBS azide, oocytes were blocked for 1 h in PBS containing 1 % bovine serum albumin (PBS-BSA), then washed three times with PBS-BSA.
Fixed, permeabilized, and blocked oocytes were incubated overnight at 4°C with rabbit monoclonal anti-HA antibody (Cell Signaling Technologies, Danvers, MA) diluted 1:1000 in PBS-BSA, then washed three times in cold PBS-BSA. Antibody-labeled oocytes were then incubated 2-3 h at room temperature with Cy3-conjugated secondary goat anti-rabbit Ig (diluted 1:500; Jackson ImmunoResearch, West Grove, PA), again thoroughly washed in PBS-BSA, and stored at 4°C until imaging. Cy3-labeled oocytes were imaged using previously reported confocal microscope settings and parameters [30] . Polypeptide abundance at or near the oocyte surface was estimated by Image J quantitation of fluorescence intensity as previously described [30] .
Statistics
Data were reported as means ± SE. Flux data were compared by Student's paired or unpaired two-tailed t tests or by ANOVA with Tukey post hoc analysis (SPSS). Some concentration-dependence datasets were fit to the MichaelisMenten equation using GraphPad Prism. (Fig. 1a, inset ) and was maximal in oocytes previously injected with ≥5 ng SLC26A1 cRNA (Fig. 1a) , consistent with previous reports [39] . Fig. 2b-e 4 2− ] was 0.24 ± 0.029 mM (R 2 = 0.78) as measured in ND96(Cl − ) and 0.24 ± 0.035 mM (R 2 = 0.68) as measured in ND96(gluconate) (Fig. 3g) , demonstrating that Cl
Results
does not regulate the apparent affinity of SLC26A1 for SO 4 2−
[o] . However, as shown in Fig. 3h , extracellular anions regulated the sensitivity of SLC26A1-mediated 35 SO 4 2− uptake to extracellular pH. The apparent proton affinity of SLC26A1 (as measured by 35 uptake was slightly reduced in ND96(gluconate) and ND96(isethionate), and substantially reduced in ND96(cyclamate). In contrast (not shown), 35 SO 4 2− uptake in Cl − -free bath solutions of sulfamate, methanesulfonate, nitrate, and phosphate was comparable in rate to that in ND96(Cl − ). Moreover, multiple sulfonate (BGood^) buffers [25] , at 40 mM concentrations failed to reduce SLC26A1-mediated 35 SO 4 2− uptake (Fig. S2 ). The inhibitory effect of cyclamate on SO 4 2− transport might reflect direct inhibition at the putative SO 4 2− transport site, or reduced cis-stimulation at the hypothetical Bcis-stimulatory anion site.^Therefore, 35 SO 4 2− uptake was measured in a 1 mM SO 4 2− bath containing constant 56 mM Cl − (producing maximal cis-stimulation; see Fig. 3a 2− efflux rate constants (±SE for n oocytes) from experiments as in (c) (**p < 0.01)
SLC26A1 mediates oxalate transport
Oocyte expression of SLC26A1 increased 14 C-oxalate uptake by almost 20-fold compared with that by uninjected oocytes (Fig. 5a ). To prevent bath oxalate chelation, the oxalate influx assay was performed in the nominal absence of both Ca 2+ and Mg
2+
, a condition which did not detectably affect influx of 35 SO 4 2− from either ND96(Cl − ) or ND96(gluconate) baths (Fig. S3 ). Bath addition of 5 mM oxalate to ND96(Cl − ) increased DIDS-sensitive 35 SO 4 2− efflux from SLC26A1-expressing oocytes 3-fold (Fig. 5b, c [o] exchange. Glyoxylate was previously identified as a substrate of rat SLC26A1 expressed in Xenopus oocytes [70] . However, 10 mM bath glyoxylate failed either to stimulate efflux of 35 
SO 4
2− from SLC26A1-expressing oocytes (Fig. 6e, f) or to cis inhibit SLC26A1-mediated 53 SO 4 2− uptake (Fig. 6g) . These data suggest that under the conditions tested in the current study, glyoxylate is not a substrate of human SLC26A1. (Fig. 7b-e) , and independent of the order of exposure to acid and alkaline pH o conditions (Fig. S4 ). 2− efflux rate constants (±SE for n oocytes) from experiments as in (h) (**p < 0.01; ***p < 0.001) 8 ). SLC26A1-mediated 35 SO 4 2− uptake was Na + -independent (Fig. 9a) , as previously reported [7, 69, 82] . In contrast,
SLC26A1-associated Cl
− influx exhibited a complex cation dependence (Fig. 9b) . 36 Cl − uptake by SLC26A1-expressing [o] cis-stimulates SLC26A1-mediated SO 4 2− transport. a SLC26A1-mediated SO 4 2− uptake (5 ng cRNA) from bath solutions containing 1 mM SO 4 2− and increasing [Cl − ], with mannitol to balance osmolarity (±SE, n = 9-10). b SLC26A1-mediated SO 4 2− uptake (5 ng cRNA) from bath solutions containing 1 mM SO 4 2− and increasing [Cl 2− efflux rate constants from experiments as in (e) (mean ± SE for n oocytes). g SLC26A1-mediated SO 4 2− uptake (5 ng cRNA) from ND96(Cl 
Cl
− uptake (~45 %) was DIDSsensitive, the remaining, DIDS-insensitive component of uptake was comparable in magnitude to 36 Cl − uptake in the absence of Na + (Fig. 9b) . This contrasts to the abolition of SLC26A1-mediated SO 4 2− uptake by 200 μM DIDS (Fig. 9a) , even in oocytes previously injected with 40 ng cRNA (data not shown). SLC26A1-associated 36 
− influx from ND96(Na +   ) was completely insensitive to 100 μl HCTZ and to 500 μM DIOA, suggesting that neither activation of endogenous oocyte Na 2− efflux rate constants of oocytes (±SE for n oocytes) as in experiments of (panel e) (*p < 0.05; **p < 0.01; ***p < 0.001) SLC26A1 is inhibited by PKC Several SLC26A1 family members are sensitive to protein kinase C (PKC) [30, 62] , and SLC26A1 has several potential PKC phosphorylation sites. As shown in Fig. 10a, exchange mediated by either SLC26A1 or HA-tagged SLC26A1 was strongly inhibited after oocyte exposure to the classical PKC activator, PMA, whereas DMSO exposure had no effects (data not shown). PKC inhibition of SLC26A1 did not reflect decreased expression at or near the oocyte surface (Fig. 10c) , in contrast to PMA-mediated reduction in oocyte surface expression accompanying PMA-medicated inhibition of SLC26A2 [30] .
Manipulations of cAMP and intracellular Ca 2+ did not alter SLC26A1 activity SLC26A1-mediated 35 (Fig. S5b) .
Mutations of highly conserved amino acid residues reveal functional similarities and differences of SLC26A1
The congenital chloride-losing diarrhea mutation SLC26A3 E293Q and the paralogous engineered mutations SLC26A4 E303Q , SLC26A2
E336Q
, and SLC26A6 E298Q exhibited loss of function in Xenopus oocytes without decrease in apparent surface expression [30, 62] . The corresponding SLC26A1 mutant SLC26A1 E295Q also exhibited 50 % reduction of 35 SO 4 2− influx (Fig. 11a) , but no reduction of 36 Cl − influx (Fig. 11b) or of apparent SLC26A1surface expression. In chicken SLC26A5/prestin, residues S398 and R399 have been proposed as substrate-binding sites, since mutation of these residues strongly disrupted prestin transport function [26] . Expression in oocytes of the corresponding mutant SLC26A1 A400C reduced SLC26A1-mediated 35 SO 4 2− uptake by only 25 % in ND96(Cl − ), and not at all in ND96(gluconate). Remarkably, 36 Cl − influx into oocytes expressing mutant SLC26A1 A400C was unaffected. However, the adjacent corresponding mutant SLC26A1 K401E (corresponding to cPrestin R399) exhibited complete loss of function in uptake assays of 35 SO 4 2− and of 36 Cl − (Fig. 11a, b) . Neither putative anion substrate binding site mutant of human SLC26A1 exhibited reduced polypeptide abundance at or near the oocyte surface (Fig. 11c) , suggesting preservation of overall transporter structure despite loss of function. HA-tagged SLC26A1 wild-type and mutant polypeptides showed similar results (data not shown).
SLC26A1 variants in the exome of a patient with recessive renal Fanconi syndrome do not confer loss of function
Inherited compound heterozygous variants SLC26A1
C41W
and SLC26A1 A56T were found in the exome of a single 4 2− efflux rate constants (±SE for n oocytes) from experiments as in (e). g SLC26A1-mediated SO 4 2− uptake from baths containing 1 mM SO 4 2− in ND96(Cl Mexican child with recessive proximal tubular (PT) Fanconi syndrome (~30×at~80 % coverage) in which mutations in Fanconi syndrome gene NaPiIIa/SLC34A1 [46] , and Fanconi-Bickel syndrome gene GLUT2/SLC5A2 [68] were not found. Both SLC26A1 variants were rare, with dbSNPreported minor allele frequencies for C41W (rs43974931) of <0.5 % and for A56T (rs142573758) of 0.02 %. The C41W variant is predicted as Bdamaging^(SIFT) or Bprobably damaging^(Polyphen2). The A56T variant is predicted as Bdamaging^(SIFT) or Bbenign^(Polyphen2). The above characteristics and the shared basolateral proximal tubular localization of SLC26A1 with GLUT2 led to evaluation of the patient's SLC26A1 variants as candidate Fanconi Syndrome genes. Both 35 SO 4 2− uptake and 14 C-oxalate uptake mediated by SLC26A1 C41W in ND96(Cl − ) were normal or slightly elevated (Fig. 12a, b) . 35 SO 4 2− uptake by SLC26A1 A56T was also normal, and 14 C-oxalate uptake was minimally decreased (Fig. 12a, b) . Interestingly, 36 Cl − uptake associated with expression of either variant was substantially increased (Fig. 12c) , as was (nominal) surface abundance of variant polypeptide (Fig. 12d, e) . However, such a gain-of-function disease mutation would likely show a dominant inheritance pattern, incompatible with the reported good health of the heterozygous parent. In addition, the hypothetical contribution of SLC26A1 A56T to proximal tubular basolateral membrane Cl − permeability [2, 58, 81] (if indeed electroneutral) should not decrease transepithelial reabsorption of HCO 3 − , glucose, or phosphate. Thus, the available functional data from expression in Xenopus oocytes do not support SLC26A1 as the renal Fanconi syndrome disease gene in this family.
SLC26A1 variants reported in a patient with nephrocalcinosis do not exhibit altered function
The rare heterozygous SLC26A1 variant SLC26A1
M132T was found in trans with the homozygous common variant Q566R in a patient with severe nephrocalcinosis requiring nephrectomy [19] . Since residue M132 is highly conserved across 
Cl
− efflux rate constants (±SE for n oocytes) from experiments as in (d) (**p < 0.01; ***p < 0.001) Fig. 8 SLC26A1 mediates 
− efflux rate constants (±SE for n oocytes) from experiments as in (c) (*p < 0.05; ***p < 0.001) species orthologs, and the M132T-encoding variant is absent from dbSNP and predicted to be pathogenic, we subjected SLC26A1
M132T to functional testing in Xenopus oocytes, in isolation and in cis with common variant Q556R. We also coexpressed cRNAs encoding the double mutant with that encoding Q566R alone, to mimic the reported patient genotype. However, neither (Fig. 13) , suggesting that variant SLC26A1
M132T did not cause nephrolithiasis in this patient.
Discussion
Prompted by our preliminary identification of SLC26A1 as a candidate gene in a case of recessive renal Fanconi syndrome, we conducted a comprehensive functional characterization of recombinant human SLC26A1 using the Xenopus oocyte heterologous expression system. SLC26A1-mediated 35 [o] exchange, but oxalate efflux in exchange for bath Fig. 11 Functional tests of select mutations in highly conserved amino acid residues of SLC26A1. a SO 4 2− uptake from ND96(Cl − ) and from ND96(gluconate) baths containing 1 mM SO 4 2− by oocytes (n = 10) previously uninjected (black bars) or injected with 5 ng cRNA encoding SLC26A1 WT 
WT or the indicated HA-tagged mutant cRNAs. Lower right, normalized HA-SLC26A1 fluorescence intensity at the oocyte periphery (mean ± SE, n = 20; ***p < 0.001) Fig. 12 Functional tests of candidate pathological missense variants of SLC26A1. Uptake of SO 4 2− (a), Mutation of residues corresponding to those crucial for SO 4 2− transport by chicken prestin/SLC26A5 altered SLC26A1-mediated 35 SO 4 2− transport in ways similar but not identical to those in prestin. However, neither SLC26A1 missense variants found in a complete Fanconi syndrome patient nor different variants previously associated with nephrolithiasis/nephrocalcinosis exhibited loss-of-function phenotypes consistent with pathogenicity. 4 2− transport
SLC26A1-mediated SO
Our determination of 0.26 mM for K 1/2 of human SLC26A1-mediated SO 4 2− uptake ( Fig. 1 ) is similar to those previously reported for rat (0.14 mM, [7] ), and reported as data not shown for mouse (0.31 mM, [41] ) and human SLC26A1 (0.19 mM, [60] ). The human K 1/2 value is appropriate for a basolateral epithelial transporter in the presence of serum SO 4 2− concentrations of~0.25-0.41 mM [49] that can double in late gestation [17] and triple during renal insufficiency [51] . Krick et al. [39] previously characterized K 1/2 values for cis-inhibition of rat SLC26A1-mediated SO 4 2− uptake by extracellular HCO 3 − , thiosulfate, sulfite, and oxalate. As we observed for human SLC26A1 (Fig. S1 ), rat SLC26A1 function appeared electroneutral in Cl − bath in both absence and presence of added SO 4 2− [39] . The related SO 4 2− transporter SLC26A2 was also shown to mediate electroneutral anion exchange [54] .
pH sensitivity of SLC26A1-mediated SO 4 2− transport
Acid pH o inhibited and alkaline pH o stimulated both influx and efflux of SO 4 2− by human SLC26A1 (Fig. 2) . In marked contrast, SO 4 2− uptake by mouse SLC26A1 was stimulated by acid pH o [82] , and rat SLC26A1-mediated SO 4 2− uptake was inhibited by alkaline pH o [39] . 4 2− together suggest an allosteric regulatory effect of SO 4 2− transport. In the absence of pH i -sensitive SO 4 2− transport by human SLC26A1, it is not straightforward to link the transporter's pH 0 -sensitivity to alkaline pH-stimulated proteoglycan sulfation [20] or to alkaline pH-stimulated metabolic Nsulfation of drugs [32] . We suggest that aa sequence differences in ecto-loops or elsewhere may explain the opposite pH sensitivites of human and rodent SLC26A1. (Fig. 4a,b ; Supplementary Fig. S4 ). Cl 2− uptake with Cl − K 1/2 of~8-13 mM (Fig. 3 ). Cl −
[o] -mediated cis stimulation of SO 4 2− uptake has also been noted as a property of SLC26A1 from mouse [82] , eel [50] , and rat [69] . However, Cl (Fig. 3e,f) . [28] . However, understanding of such regulation is more challenging for a basolateral transporter such as SLC26A1 in proximal tubule and enterocytes exposed to interstitial fluid, for which a yet undefined anion, active in the presence of saturating Cl − , may be a more potent physiological ligand of the regulatory ectosite. Recently, SLC26A1 has been localized to the apical membrane in maturation phase ameloblasts in developing teeth of rat [85] , a context in which physiological regulation by Cl
−
[o] might occur. Alternatively, the regulatory ectobinding site might be an evolutionary legacy from ancestral SLC26 genes or the conditions in which they functioned.
Transport of oxalate and other anions
SLC26A1 from mouse [82] and rat [39] was previously shown to take up oxalate. Ethylene glycol-induced hyperoxaluria in female (but not male) rats was accompanied by elevated hepatic and renal levels of SLC26A1 polypeptide, but not mRNA [10] . Human SLC26A1 displayed oxalate influx higher in Cl (Fig. 5) . This preferentially vectorial oxalate transport is consistent with the hypothesis that basolateral oxalate uptake by enterocytes is mediated by SLC26A1 as part of a transepithelial pathway that includes apical oxalate secretion into the gut lumen by SLC26A6 [18, 48] . The macroscopically unidirectional transport may reflect a very low affinity of SLC26A1 for intracellular oxalate, or much higher affinities for other coextant substrate anions at the intracellular substrate binding site. However, such a system is not active throughout the gut, as evidenced by normal ex vivo oxalate secretion rates by the isolated Slc26a1 −/− mouse duodenum [38] .
Human SLC26A1-mediated exchange of SO 4 2−
[i] for bath HCO 3 − and for bath thiosulfate (Fig. 6a-d) resembled that mediated by rat SLC26A1 [39] . Thus, SLC26A1 may play a role in the action of exogenous thiosulfate in treatment or prophylaxis of calciphylaxis [53, 56] and possibly also in the metabolism of H 2 S, both a precursor of endogenous thiosulfate and a product of exogenous thiosulfate [42] . Unlike rat SLC26A1 [70] , recombinant human SLC26A1 did not exhibit glyoxylate transport (Fig. 6e-g ), despite the ability of chronic glyoxylate exposure to increase SLC26A1 mRNA and SO 4 2− uptake in human HepG2 cells [70] . Thus, our Xenopus oocyte data do not support the otherwise attractive model of hepatic SLC26A1-mediated glyoxylate/oxalate exchange proposed by Schnedler et al. [70] .
Transport of Cl − associated with SLC26A1 expression in Xenopus oocytes Human SLC26A1 mediated robust uptake of Cl − which is increased further by acid pH o (Fig. 7a) , in contrast to 
Cl
− efflux into baths of Cl − or gluconate were of lower rate and lower DIDS sensitivity than was the case for SLC26A1-mediated SO 4 2− transport (Fig. 8) . Among other SLC26 polypeptides, acid pH o also increased SLC26A9-mediated Cl − currents [64, 65] .
Unlike the Na + -independence of SLC26A1-mediated SO 4 2 − transport, SLC26A1-associated Cl − flux displayed partial Na + dependence (Fig. 9) 
PKC regulation of SLC26A1
PKC activation by PMA was first shown to downregulate SLC26A6 activity through decreased cell surface expression, and pharmacological approaches suggested regulation by PKCδ [29] . Documentation of inhibition by PMA-mediated activation of PKC was extended to SLC26A2 [30] and SLC26A3, but SLC26A4 was unaffected by PMA. Activated PKCδ was more definitively implicated as inhibitor of SLC26A2, −A3, and -A6 through attenuation of inhibition by co-expressed kinase-dead PKCδ [63] . Here we have demonstrated PMA-mediated inhibition of SLC26A1 by a mechanism other than regulation of surface expression (Fig. 10 ). This PMA response may reflect involvement of a different PKC isoform. Further work will determine whether SLC26A1 inhibition by PMA is mediated via direct phosphorylation or requires intermediate signaling steps.
Divergent effects of SLC26A1 mutations on transport of SO 4 2− and Cl
−
The structural fold of paralogous SLC26 proteins accommodates anion exchangers of varied selectivity and mechanism, anion channels, and proteins with apparent plasticity of anion selectivity and mechanism [1, 74] . Therefore, the functional consequences of mutation in selected residues previously shown crucial for anion transport activity in other SLC26 family members were tested in SLC26A1. Human SLC26A3 disease mutant E293Q exhibited loss of 36 Cl − / anion exchange function without decrease in surface expression [63] . Xenopus oocyte functional expression data suggest that the SLC26A1 variants identified in a patient with renal Fanconi syndrome and a patient with nephrolithiasis/calcinosis do not likely contribute to the pathogenesis of these conditions. SLC26A1 variants found in a patient with Fanconi syndrome exhibited no decrease in transport of either SO 4 2− , oxalate, or Cl − (Fig. 12) . Indeed, the C41W variant increased transport of both Cl − and SO 4 2− without change in oocyte surface expression. In contrast, variant A56T increased Cl − transport by 4-fold but slightly decreased oxalate transport, both in parallel with 4-fold 65 % increased polypeptide expression at or near the oocyte surface. These functional properties do not suggest a causative role for these SLC26A1 mutants in renal Fanconi syndrome.
The rare heterozygous SLC26A1 variant M132T and the common homozygous variant Q556R, found together in a patient with recurrent nephrolithiasis and nephrocalcinosis [19] , did not alter transport of SO 4 2− or oxalate, whether expressed individually or co-expressed (Fig. 13) . Thus, the functional properties of these variants expressed in Xenopus oocytes do not suffice to explain nephrolithiasis or nephrocalcinosis in this patient. We cannot rule out the possibility that detection of impaired trafficking, or transport phenotypes of either the Fanconi variants or the nephrolithiasis/ calcinosis variants of SLC26A1 might require expression inpolarized mammalian epithelial cells that express yet unidentified interaction partners of SLC26A1. Nonetheless, as a basolateral oxalate uptake mechanism of intestinal and proximal tubular epithelial cells, inclusion of the SLC26A1 gene in genetic variant screens of nephrolithiasis/calcinosis patients is reasonable.
Conclusion
The functional properties of human SLC26A1 emphasize the context-dependent functional complexity among not only paralogs but even species orthologs of SLC26 anion transporter polypeptides. Although human SLC26A1 shared with its paralogs the ability to mediate apparently electroneutral, cisCl − -stimulated exchange of sulfate and oxalate, and transport of bicarbonate and thiosulfate, it differed from those paralogs in several notable ways. Human SLC26A1 exhibited pH o -dependent sulfate exchange that was opposite to that of rodent SLC26A1, as well as opposite to that exhibited by human SLC26A1-associated Cl − transport. Human SLC26A1 differed from rat SLC26A1 in its inability to mediate oxalate/ glyoxalate exchange. The human SLC26A1-associated transport of Cl − exhibited partial and limited cation-dependence. In contrast to other human SLC26 anion exchangers, human SLC26A1 inhibition by PKC was unassociated with decreased polypeptide expression at or near the oocyte surface. The major mechanistic finding presented here is the demonstration that the cis-stimulation of human SLC26A1-mediated anion exchange by Cl
−
[o] is a V max effect mediated by allosteric regulation of the transporter's pH o sensitivity. The recently published crystal structure of the TMD of bacterial SulP/SLC26 multi-anion transporter SLC26Dg [23] , and the confirmation of its previously suspected contextual modulation of anion selectivity [3, 23, 74] will aid in the structural analysis of allosteric regulatory interplay by extracellular protons and anions in the control of human SLC26A1 activity.
